Eurocine Vaccines is publically listed at Spotlight Stock Market XSAT, Sweden, with the ticker EUCI.
To be notified with news, sign up to our newsfeed =>
Legal Advisor is Lindahl.
Sedermera is our Financial Advisor.
Patent and Intellectual Property (IP) advisors are Zacco and Potter Clarkson.
Link to an interview in English with CEO Hans Arwidsson:
Interview with Eurocine Vaccines´ CEO
Unit Issue June 2021
Unitemission, juni 2021
The Board of Eurocine Vaccines has, with the support of authorization from the Annual General Meeting, decided on a unit issue to finance most of the preparatory activities before the start of the first clinical study on the vaccine candidate against chlamydia. The unit issue can initially provide a maximum of approximately SEK 31.6 million before issuing costs. Through the rights issue of units, free warrants of series TO 4 will be issued, which can provide a maximum of SEK 19.7 million before issuing costs, in connection with the warrant exercise in March 2022. In addition to the development activities in the chlamydia project, the capitalization will finance intensified business development, partly with the aim of preparing potential partners for the chlamydia vaccine candidate and partly for the identification and evaluation of additional vaccine candidates.
In connection with the unit issue, the Board of Eurocine Vaccines has produced the following documents in English:
For the full Prospectus (in Swedish), please see below.
Styrelsen i Eurocine Vaccines har, med stöd av bemyndigande av årsstämman, vi beslutat om en företrädesemission av units för att finansiera huvuddelen av de förberedande aktiviteterna inför starten av den första kliniska studien med vaccinkandidaten mot klamydia. Unitemissionen kan initialt tillföra maximalt cirka 31,6 MSEK före emissionskostnader. Genom unitemissionen kommer vederlagsfria teckningsoptioner att emitteras, vilka kan tillföra maximalt 19,7 MSEK före emissionskostnader, i samband med optionsinlösen i mars 2022. Utöver utvecklingsaktiviteterna i klamydiaprojektet, kommer unitemissionen att finansiera en intensifierad affärsutveckling med syfte att dels förbereda potentiella partners för klamydiavaccinkandidaten, dels identifiera och utvärdera ytterligare vaccinkandidater.
Länk till intervju på svenska med VD Hans Arwidsson:
Intervju med Eurocine Vaccines VD
Med anledning av företrädesemissionen av units har styrelsen i Eurocine Vaccines AB upprättat följande dokument:
Latest Presentation
CEO Dr. Hans Arwidsson presents at Aktieportföljen Live, 26 May 2021.
Future Financial Reports
Annual Report July 2020 – June 2021 planned to be available 31 August 2021
Existing Financial Reports
Interim Report July 2020-March 2021 =>